We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of New Biological Markers for Prediction of Severe Acute Pancreatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00786591
Recruitment Status : Completed
First Posted : November 6, 2008
Last Update Posted : December 31, 2012
Sponsor:
Collaborators:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Acute pancreatitis refers to inflammation of the pancreas and is associated with sudden onset of severe abdominal pain, often accompanied by transient systemic manifestations, including fever. In the majority of cases, the inflammatory process is self limiting and patient recovers uneventfully; however, in about 20% to 30% of the cases, a protracted clinical course ensues and the disease may progress to a severe necrotizing form, often triggering a systemic inflammatory response syndrome during which time, acute respiratory distress syndrome, renal failure, shock, and disseminated intravascular coagulation may occur. In the worst sequelae, multiple organ dysfunctions may follow and death supervene. The clinical outcome of patients suffering from severe acute pancreatitis depends to a great extent on the early diagnosis and prediction of severity and timely therapeutic intervention to prevent local and systemic complications. However, the course of the disease is often difficult to predict from the outset. Currently, there is still no single clinical or laboratory test that can be considered the "gold standard" for diagnosis and/or assessment of severity of acute pancreatitis. For a disease that may progress rapidly without apparent sign, the ideal marker for the prediction of disease severity in a patient would be one that is measurable rapidly and easily, besides being able to fulfill all the other criteria required of a good biological marker. To identify such a potential marker for acute pancreatitis requires understanding of the pathophysiological process underlying the rapid progression of a fulminant course of the disease. Although much remains to be elucidated, recent studies in animals have suggested that inflammatory mediators substance P and hydrogen sulfide may play critical roles. This study will evaluate if inflammatory mediators substance P and hydrogen sulfide are upregulated early on in the disease process, and if the levels of their elevation predict disease severity.

Condition or disease
Acute Pancreatitis

Study Design

Study Type : Observational
Actual Enrollment : 75 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Clinical Evaluation of Novel Biological Markers for the Prediction of Severe Acute Pancreatitis
Study Start Date : June 2006
Primary Completion Date : July 2009
Study Completion Date : July 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pancreatitis
U.S. FDA Resources

Groups and Cohorts

Group/Cohort
Acute Pancreatitis Patients
Patients presenting with clinical features compatible with acute pancreatitis
Control
Preoperative patients going for elective cholecystectomy


Outcome Measures

Primary Outcome Measures :
  1. Levels of substance P and hydrogen sulfide in blood measured 6-hourly over a time course of 3 days [ Time Frame: On admission to hospital, blood sampling will be done every 6 hours for 3 days ]

Secondary Outcome Measures :
  1. Disease severity index derived from: (i) Ranson score; (ii) Acute Physiology and Chronic Health Evaluation (APACHE) II scores; (iv) Glasgow and (v) Multi-Organ System Failure (MOSF) Score [ Time Frame: Within 3 days of hospital admission ]

Biospecimen Retention:   Samples With DNA
Whole blood; Serum

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with clinical presentation suggestive of acute pancreatitis
Criteria

Inclusion Criteria:

The patient should fulfill all of the following criteria:

  • The subject should be at least 18 years of age.
  • Clinical features compatible with acute pancreatitis.
  • First symptoms of acute pancreatitis not more than 72 hours before enrolment.
  • Serum amylase level above 480 U/dl (normal 60-160 U/dl or 2-hour urinary amylase greater than 1120 U (normal 280 U).
  • Serum lipase levels greater than 2 U (normal < 1 U).
  • Patient has signed consent form regarding participation in the study.

Exclusion Criteria:

The patient should not present any of the following criteria:

  • Symptoms of acute pancreatitis present for more than 72 hours
  • Clinical evidence of sepsis or other inflammatory diseases.
  • Clinical evidence of disorders/disease known to affect endogenous regulation of substance P, e.g. asthma, immune-complex-mediated lung injury, arthritis.
  • Age under 18 years
  • Pregnancy
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00786591


Locations
Singapore
National University Hospital
Singapore, Singapore, 119074
Sponsors and Collaborators
National University Hospital, Singapore
National University, Singapore
National Medical Research Council (NMRC), Singapore
Investigators
Principal Investigator: Khek Yu Ho, MD National University Hospital, Singapore
More Information

Publications:
Responsible Party: Medicine, Professor & Senior Consultant Gastroenterologist, Ho Khek Yu, National University Hospital, Singapore
ClinicalTrials.gov Identifier: NCT00786591     History of Changes
Other Study ID Numbers: D/05/194
First Posted: November 6, 2008    Key Record Dates
Last Update Posted: December 31, 2012
Last Verified: December 2012

Keywords provided by Medicine, National University Hospital, Singapore:
Acute pancreatitis
biological markers
substance P
hydrogen sulfide
disease severity index

Additional relevant MeSH terms:
Pancreatitis
Pancreatic Diseases
Digestive System Diseases